ZNF507 affects TGF-β signaling via TGFBR1 and MAP3K8 activation in the progression of prostate cancer to an aggressive state
Abstract Background The progression of prostate cancer (PC) to the highly aggressive metastatic castration-resistant prostate cancer (mCRPC) or neuroendocrine prostate cancer (NEPC) is a fatal condition and the underlying molecular mechanisms are poorly understood. Here, we identified the novel tran...
Main Authors: | Wookbong Kwon, Seong-Kyoon Choi, Daehwan Kim, Hyeon-Gyeom Kim, Jin-Kyu Park, Jee Eun Han, Gil-Jae Cho, Sungho Yun, Wookyung Yu, Se-Hyeon Han, Yun-Sok Ha, Jun Nyung Lee, Tae Gyun Kwon, Dong-Hyung Cho, Jun-Koo Yi, Myoung Ok Kim, Zae Young Ryoo, Song Park |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-09-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13046-021-02094-3 |
Similar Items
-
Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer
by: Bram De Laere, et al.
Published: (2021-03-01) -
Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
by: Moran Gadot, et al.
Published: (2020-04-01) -
Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
by: Joshua P. Schiff, et al.
Published: (2019-05-01) -
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
by: Fatima Karzai, et al.
Published: (2018-12-01) -
Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
by: Murali Kesavan, et al.
Published: (2021-03-01)